Edwards Lifesciences Corp (EW) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.

Total Assets Chart for Edwards Lifesciences Corp

Edwards Lifesciences Corp (EW) total assets for FY2025 were USD 13.7B, a 4.9% change from FY2024. Edwards Lifesciences Corp's total assets grew from USD 1.4B in 1999 to USD 13.7B in 2025 (853.2% over 26 years). Total assets compound annual growth rate: 5-year CAGR of 13.6%, 10-year CAGR of 12.9%, 20-year CAGR of 12.8%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$51.43B
Implied Share Price
$89.32
Enterprise Value
$48.04B
Revenue (TTM)
$6.51B
EBITDA
$2.00B
Profit Margin
15.43%
Trailing P/E
53.17
Forward P/E
29.85
Price/Book (MRQ)
4.86
Price/Sales (TTM)
7.91
EV/EBITDA
29.08
EV/Revenue
7.38
Dividend Yield
—
Book Value
$17.90
Free Cash Flow (FY2025)
$1.33B
Free Cash Flow Yield
2.60%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.